Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.12.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Arne Strotmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Melphalan, Hematopoietic Stem Cell Transplantation, Consolidation Chemotherapy. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: High-dose chemotherapy with melphalan (HDCT) and autologous stem cell transplantation (ASCT) represents a gold standard treatment for younger multiple myeloma (MM) patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
- Department for Hematology and Oncology, University Hospital Schleswig-Holstein, University Cancer Center Schleswig-Holstein and University of Luebeck, Luebeck, Germany.
- Department of Hematology and Medical Oncology, INDIGHO laboratory, University Medical Center Goettingen (UMG), Goettingen, Germany.
- Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany. Electronic address: evgenii.shumilov@ukmuenster.de.
- Department for Hematology and Oncology, University Hospital Schleswig-Holstein, University Cancer Center Schleswig-Holstein and University of Luebeck, Luebeck, Germany. Electronic address: cyrus.khandanpour@uksh.de.
Zitieren
APA
Strotmann, A., Leitner, T., Mazzeo, P., Evers, G., Pohlmann, A., Eisfeld, C., Seib, M., von Bubnoff, N., Lenz, G., Shumilov, E., & Khandanpour, C. (2025). Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.008
Vancouver
Strotmann A, Leitner T, Mazzeo P, Evers G, Pohlmann A, Eisfeld C, et al. Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.12.008
BibTeX
@article{Strotmann2025,
author = {Strotmann, Arne and Leitner, Theo and Mazzeo, Paolo and Evers, Georg and Pohlmann, Alexander and Eisfeld, Christine and Seib, Maximilian and von Bubnoff, Nikolas and Lenz, Georg and Shumilov, Evgenii and Khandanpour, Cyrus},
title = {Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.12.008}
}
EUVIMED